Pixuvri® (Pixantrone Dimaleate, BBR 2778): From Lab to Market

Author(s): A. Paul Krapcho

Journal Name: Current Organic Chemistry

Volume 19 , Issue 10 , 2015

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


This review will trace the steps in the development of pixantrone dimaleate (initial code BBR 2778, Pixruvi®), an anthracenedione chemotype, as a chemotherapeutic agent. This drug exhibits reduced cardiotoxicity in comparison to anthracyclines and mitoxantrone. Synthetic pathways, biological evaluations and mechanistic considerations will be discussed. On May 10, 2012, the European Medicines Agency granted a conditional marketing approval to CTI Biopharma for pixantrone dimaleate for the treatment of adults suffering from multiple relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). Potential applications of pixantrone dimaleate for the treatment of multiple sclerosis and other maladies will be presented.

Keywords: BBR-2778, cardiotoxicity, non-Hodgkin, lymphoma, pixantrone, Pixuvri®.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 27 May, 2015
Page: [886 - 897]
Pages: 12
DOI: 10.2174/1385272819666150119224450
Price: $58

Article Metrics

PDF: 17